Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of EBITDA Margin data on record, last reported at 117.91% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 5049.0% year-over-year to 117.91%; the TTM value through Dec 2025 reached 115.89%, down 2482.0%, while the annual FY2025 figure was 115.89%, 2499.0% down from the prior year.
  • EBITDA Margin reached 117.91% in Q4 2025 per MRVI's latest filing, down from 98.56% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 76.59% in Q3 2021 and bottomed at 239.93% in Q3 2024.
  • Average EBITDA Margin over 5 years is 16.52%, with a median of 13.25% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: tumbled -21688bps in 2024, then surged 14137bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 66.14% in 2021, then fell by -19bps to 53.37% in 2022, then tumbled by -118bps to 9.64% in 2023, then crashed by -599bps to 67.42% in 2024, then plummeted by -75bps to 117.91% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 117.91% in Q4 2025, 98.56% in Q3 2025, and 139.84% in Q2 2025.